Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PNN001
MIFTS: 51

Panniculitis

Categories: Skin diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Panniculitis

About this section

MalaCards integrated aliases for Panniculitis:

Name: Panniculitis 11 75 28 53 43 14 16 71 33
Nodular Panniculitis 33

Classifications:

MalaCards categories:
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 31
ICD11: 33


External Ids:

Disease Ontology 11 DOID:1526
ICD9CM 34 729.30
MeSH 43 D015434
NCIt 49 C112112
SNOMED-CT 68 268122002
ICD10 31 M79.3
ICD11 33 1056888958
UMLS 71 C0030326
Sources

Summaries for Panniculitis

About this section

Disease Ontology: 11 A skin disease that is characterized by inflammation of subcutaneous adipose tissue.

MalaCards based summary: Panniculitis, also known as nodular panniculitis, is related to proteasome-associated autoinflammatory syndrome 1 and proteasome-associated autoinflammatory syndrome 3, and has symptoms including myalgia, pruritus and exanthema. An important gene associated with Panniculitis is TIA1 (TIA1 Cytotoxic Granule Associated RNA Binding Protein), and among its related pathways/superpathways are Innate Immune System and MIF Mediated Glucocorticoid Regulation. The drugs Cyclophosphamide and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include skin, pancreas and breast, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Reduced mammosphere formation

Wikipedia: 75 Panniculitis is a group of diseases whose hallmark is inflammation of subcutaneous adipose tissue (the... more...
Sources

Related Diseases for Panniculitis

About this section

Diseases related to Panniculitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 738)
# Related Disease Score Top Affiliating Genes
1 proteasome-associated autoinflammatory syndrome 1 32.3 PSMB8 PSMB4 IFNG
2 proteasome-associated autoinflammatory syndrome 3 31.6 PSMB9 PSMB4
3 pancytopenia 30.9 NCAM1 IL2RA IFNG CSF3
4 burkitt lymphoma 30.8 MYC FAS CSF3 CASP3
5 hemophagocytic lymphohistiocytosis 30.7 NCAM1 IL2RA IFNG HAVCR2 GZMB CSF3
6 aplastic anemia 30.6 MYC IFNG GZMB FASLG FAS CSF3
7 primary cutaneous gamma-delta t-cell lymphoma 30.6 TIA1 NCAM1 GZMB
8 peripheral t-cell lymphoma 30.6 TIA1 NCAM1 IL2RA GZMB
9 primary cutaneous t-cell non-hodgkin lymphoma 30.6 TIA1 IL2RA IFNG GZMB FAS
10 lymphoma, hodgkin, classic 30.6 TIA1 PSMB9 IL2RA GZMB CSF3
11 systemic lupus erythematosus 30.5 IL2RA IFNG HAVCR2 FASLG FAS CSF3
12 lymphoma 30.5 TIA1 MYC IL2RA HAVCR2 GZMB FAS
13 nasal type extranodal nk/t-cell lymphoma 30.4 TIA1 NCAM1 GZMB
14 sjogren syndrome 30.4 IL2RA GZMB FASLG FAS
15 lymphoproliferative syndrome 30.4 TIA1 FASLG FAS
16 b-cell lymphoma 30.4 TIA1 MYC FAS CASP3 BTK
17 mature t-cell and nk-cell lymphoma 30.3 TIA1 NCAM1 MYC GZMB
18 behcet syndrome 30.2 OTULIN IL2RA IFNG FAS CSF3
19 leukemia, chronic myeloid 30.2 MYC GZMB CSF3 CASP3 BRAF
20 relapsing-remitting multiple sclerosis 30.2 IL2RA IFNG FAS
21 hepatitis a 30.2 SERPINA1 IFNG HAVCR2
22 alopecia areata 30.2 IL2RA IFNG GZMB FASLG
23 hepatitis 30.1 SERPINA1 HAVCR2 FASLG FAS
24 viral infectious disease 30.1 IL2RA IFNG GZMB FAS
25 lymphadenitis 30.1 IL2RA IFNG FASLG FAS CASP3
26 pulmonary emphysema 30.1 SERPINA1 IFNG CASP3
27 myelodysplastic syndrome 30.1 NCAM1 MYC GZMB FASLG FAS CSF3
28 autoimmune disease 30.1 PSMB9 IL2RA IFNG HAVCR2 FASLG FAS
29 nakajo syndrome 30.0 PSMB8 PSMB4
30 lymphomatoid granulomatosis 30.0 TIA1 GZMB
31 pancreatic cancer 30.0 SERPINA1 MYC IFNG GZMB FASLG FAS
32 orbit lymphoma 30.0 TIA1 NCAM1
33 skin disease 29.9 NCAM1 MYC IFNG GZMB CSF3 CASP3
34 lichen sclerosus et atrophicus 29.9 TIA1 GZMB
35 peripheral nervous system disease 29.9 NCAM1 MYC IFNG CSF3 CASP3
36 acute graft versus host disease 29.8 IL2RA IFNG CSF3
37 mycosis fungoides 29.8 TIA1 NCAM1 IL2RA IFNG GZMB
38 lymphopenia 29.8 IL2RA IFNG FASLG FAS BTK
39 immune deficiency disease 29.8 IL2RA IFNG FASLG FAS BTK
40 lymphoma, non-hodgkin, familial 29.8 NCAM1 MYC IL2RA GZMB FAS CSF3
41 childhood lymphoma 29.8 TIA1 MYC
42 tropical spastic paraparesis 29.7 IL2RA IFNG FASLG
43 celiac disease 1 29.7 TIA1 SERPINA1 NCAM1 IL2RA IFNG GZMB
44 conjunctivitis 29.7 IL2RA IFNG BTK
45 malaria 29.7 SERPINA1 IL2RA IFNG HAVCR2 GZMB FASLG
46 myeloma, multiple 29.6 NCAM1 MYC FASLG FAS CSF3 CASP3
47 viral hepatitis 29.6 SERPINA1 IFNG FASLG FAS
48 leukemia, acute myeloid 29.6 NCAM1 MYC IFNG HAVCR2 GZMB FASLG
49 type 1 diabetes mellitus 29.6 PSMB9 PSMB8 IFNG FASLG FAS
50 sezary's disease 29.6 TIA1 NCAM1 MYC IL2RA IFNG

Graphical network of the top 20 diseases related to Panniculitis:



Diseases related to Panniculitis
Sources

Symptoms & Phenotypes for Panniculitis

About this section

UMLS symptoms related to Panniculitis:


myalgia; pruritus; exanthema; decreased adipose tissue; other musculoskeletal symptoms referable to limbs; pain in limb; integumentary system signs and symptoms

GenomeRNAi Phenotypes related to Panniculitis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.16 CASP3 FAS GZMB IL2RA NAV3 PSMB8
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.16 CASP3 FAS GZMB IL2RA NAV3 PSMB8
3 Reduced mammosphere formation GR00396-S 9.23 BRAF CSF3 FAS FASLG IL2RA MYC

MGI Mouse Phenotypes related to Panniculitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.13 BRAF BTK CASP3 CSF3 FAS FASLG
2 neoplasm MP:0002006 10.07 BRAF BTK FAS FASLG GZMB IFNG
3 hematopoietic system MP:0005397 10.03 BRAF BTK CASP3 CSF3 FAS FASLG
4 digestive/alimentary MP:0005381 9.92 BRAF BTK CASP3 FAS FASLG IFNG
5 mortality/aging MP:0010768 9.8 BRAF BTK CASP3 FAS FASLG GZMB
6 integument MP:0010771 9.28 BRAF BTK CASP3 CSF3 FAS FASLG
Sources

Drugs & Therapeutics for Panniculitis

About this section

Drugs for Panniculitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 56)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
2
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
3
Etoposide Approved Phase 4 33419-42-0 36462
4
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
5
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
6
Ifosfamide Approved Phase 4 3778-73-2 3690
7
Doxorubicin Approved, Investigational Phase 4 23214-92-8 31703
8
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 4112 126941
9
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
10
Palifosfamide Investigational Phase 4 31645-39-3 100427
11
Pirarubicin Investigational Phase 4 72496-41-4 4844
12 Immunologic Factors Phase 4
13 Alkylating Agents Phase 4
14 Antirheumatic Agents Phase 4
15 Antineoplastic Agents, Alkylating Phase 4
16 Immunosuppressive Agents Phase 4
17 Folic Acid Antagonists Phase 4
18 Folate Phase 4
19 Vitamin B9 Phase 4
20 Vitamin B Complex Phase 4
21
Etoposide phosphate Phase 4 16760419
22 Antineoplastic Agents, Hormonal Phase 4
23 Anti-Bacterial Agents Phase 4
24 Antimitotic Agents Phase 4
25 Hormones Phase 4
26 Hormone Antagonists Phase 4
27 Tubulin Modulators Phase 4
28 glucocorticoids Phase 4
29 Anti-Inflammatory Agents Phase 4
30 Antibiotics, Antitubercular Phase 4
31 Liposomal doxorubicin Phase 4
32 Antimetabolites Phase 4
33 Dermatologic Agents Phase 4
34
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
35
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3 3680
36
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 3003 5743
37
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
38
Brentuximab vedotin Approved, Investigational Phase 2 914088-09-8
39
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
40 Immunoglobulins, Intravenous Phase 2
41 Immunoglobulins Phase 2
42 Immunoconjugates Phase 2
43 Antibodies, Monoclonal Phase 2
44 Antibodies Phase 2
45 Antineoplastic Agents, Immunological Phase 2
46 10-deazaaminopterin Phase 1, Phase 2
47 Immunoglobulin G Phase 1, Phase 2
48
Rituximab Approved Phase 1 174722-31-7
49
Triethylenetetramine Approved, Investigational 112-24-3 5565
50
Cholecalciferol Approved, Nutraceutical, Vet_approved 67-97-0, 1406-16-2 5280795 10883523

Interventional clinical trials:

(show all 13)
# Name Status NCT ID Phase Drugs
1 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Unknown status NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
2 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With Peripheral T-cell Lymphoma (PTCL) Unknown status NCT02533700 Phase 2 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
3 Phase II Study of Brentuximab Vedotin in Combination With Pembrolizumab in Patients With Recurrent Systemic Peripheral T-Cell Lymphoma (PTCL) Recruiting NCT04795869 Phase 2 Brentuximab Vedotin
4 A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas Recruiting NCT03598998 Phase 1, Phase 2 Pralatrexate
5 A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas Recruiting NCT05475925 Phase 1, Phase 2 DR-01
6 Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in T and NK-Cell Lymphomas Completed NCT01445535 Phase 1 Etoposide;Prednisone;Vincristine;Cyclophosphamide;Doxorubicin
7 Mesenteric Panniculitis : Review of Consecutive Abdominal MDCT Examinations With a Matched-pair Analysis Completed NCT03316001
8 Prospective Collection of Data in Pts With Peripheral T-Cell Lymphoma: PTCL,NOS;AITL; Extranodal NK/T-cell;Enteropathy-type; Hepatosplenic γ-δ; Subcutaneous Panniculitis-like; ALCL,Primary Systemic Type. By the Intl. T-Cell Lymphoma Project Completed NCT01142674
9 A Pilot Feasibility Trial of the Tolerability of Oral Salvia Hispanica and Its Effect on Blood Fatty Acids and Stool Microbiome in Patients With Treated Non-Hodgkin Lymphoma Completed NCT02652715
10 Cyclophosphamide in the Treatment of Panniculitis Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes Recruiting NCT03936829 Cyclophosphamide
11 Effect of Vitamin D Replacement on Tumor Response and Survival Parameters for Vitamin D Insufficient Patients With Cancer Suspended NCT01787409
12 Prospective Study of Functional and Quality of Life Outcomes in Panniculectomy Patients Terminated NCT01464658
13 Inflammation and Oxidative Stress of Adipose Tissue in Obese and Non-obese Patients Having Sleep Apnea Syndrome Terminated NCT01196845

Search NIH Clinical Center for Panniculitis

Cochrane evidence based reviews: panniculitis

Sources

Genetic Tests for Panniculitis

About this section

Genetic tests related to Panniculitis:

# Genetic test Affiliating Genes
1 Panniculitis 28
Sources

Anatomical Context for Panniculitis

About this section

Organs/tissues related to Panniculitis:

MalaCards : Skin, Pancreas, Breast, Bone Marrow, Myeloid, Colon, Kidney
Sources

Publications for Panniculitis

About this section

Articles related to Panniculitis:

(show top 50) (show all 3515)
# Title Authors PMID Year
1
New Findings in PiZZ alpha1-antitrypsin deficiency-related panniculitis. Demonstration of skin polymers and high dosing requirements of intravenous augmentation therapy. 53 62
19218787 2009
2
Alpha1-antitrypsin deficiency: incidence and implications. 53 62
16327507 2005
3
A review of alpha-1 antitrypsin deficiency. 53 62
17136953 2005
4
A review of alpha-1 antitrypsin deficiency. 53 62
16088434 2005
5
Alpha-1-antitrypsin associated panniculitis: the MS variant. 53 62
15389208 2004
6
Nasal-type natural killer cell lymphoma preceded by benign panniculitis arising in an asymptomatic HTLV-1 carrier. 53 62
12956685 2003
7
alpha 1-antitrypsin deficiency-associated panniculitis: resolution with intravenous alpha 1-antitrypsin administration and liver transplantation. 53 62
9039946 1997
8
Subcutaneous entomophthoromycosis in an immunocompetent individual: a localised forearm swelling. 62
36455985 2022
9
Subcutaneous panniculitis-like T-cell lymphoma associated with methotrexate treatment. 62
35892130 2022
10
Subcutaneous panniculitis-like T-cell lymphoma: an unusual cause of right thigh hypertrophy. 62
36460313 2022
11
Mesenteric panniculitis is associated with cardiovascular risk-factors: A case-control study. 62
35853820 2022
12
Erythema nodosum with incidental calciphylaxis secondary to zoledronic acid and denosumab. 62
36184744 2022
13
Infectious panniculitis: an inpatient cohort. 62
34813076 2022
14
Primary cutaneous gamma-delta T-cell lymphoma masquerading as leukemia cutis in a patient recently diagnosed with small lymphocytic lymphoma: Clues to the diagnosis. 62
35841268 2022
15
Expression pattern and diagnostic utility of BCL11B in mature T- and NK-cell neoplasms. 62
35864006 2022
16
Neutrophilic dermatoses. 62
35870984 2022
17
Pancreatic panniculitis and polyarthropathy due to undifferentiated pleomorphic sarcoma. 62
36425661 2022
18
Resolution of feline Mycobacterium panniculitis despite protracted treatment with methylprednisolone acetate. 62
35934909 2022
19
Centrifugal lipodystrophy on a spectrum with lupus erythematosus panniculitis in children and efficacy and safety of hydroxychloroquine: A clinicopathological study. 62
36100983 2022
20
Rapid cytologic diagnosis of subcutaneous fat necrosis of the newborn. 62
36411587 2022
21
Clinical Epidemiology, Pathology, and Molecular Investigation of Lumpy Skin Disease Outbreaks in Bangladesh during 2020-2021 Indicate the Re-Emergence of an Old African Strain. 62
36423138 2022
22
Application of cryolipolysis in adipose tissue: A systematic review. 62
35869825 2022
23
C-Reactive Protein as a Diagnostic Marker in Dogs: A Review. 62
36290272 2022
24
Immune checkpoint inhibitor-associated panniculitis: clinicopathological features and cytokine profiles. 62
35686625 2022
25
Clinical and Pathological Characteristics and Outcomes Among Patients With Subcutaneous Panniculitis-like T-Cell Lymphoma and Related Adipotropic Lymphoproliferative Disorders. 62
36001337 2022
26
Painful lower limb nodules as first symptom of resectable pancreatic acinar cell cancer: a case report. 62
36195885 2022
27
TCL-084 Subcutaneous Panniculitis-Like T-Cell Lymphoma With Co-Existing Lupus Panniculitis: A Case Report. 62
36164122 2022
28
Cold Panniculitis and Subcutaneous Fat Necrosis of the Newborn: The Continual Sequelae in the Non-pharmacological Conversion of Supraventricular Tachycardia. 62
36214187 2022
29
Scedosporium apiospermum infection mimicking erythema nodosum: the importance of culture samples in immunocompromised patients with panniculitis. 62
36256469 2022
30
Alpha-1 antitrypsin deficiency-associated panniculitis. 62
33516773 2022
31
Relapsing subcutaneous panniculitis-like T-cell lymphoma with B symptoms, remitting on low dose methotrexate. 62
36210058 2022
32
Subcutaneous panniculitis-like T-cell lymphoma after COVID-19 vaccination. 62
35966352 2022
33
Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphoma. 62
36070587 2022
34
CD20-positive subcutaneous panniculitis-like T-cell lymphoma presenting as polycranial neuropathy: A CARE-compliant case report and literature review. 62
36107521 2022
35
Chronic Cutaneous Lupus Erythematosus in a White Population: Dermoscopic Characteristics by Clinical Subtype, Lesion Location and Disease Duration. 62
35996053 2022
36
Clinicopathological Features of Cutaneous Findings of SARS-CoV-2 Infection. 62
36128840 2022
37
Cutaneous Involvement of Extranodal NK/T Cell Lymphoma, Nasal Type, a Clinical and Histopathological Mimicker of Various Skin Diseases. 62
36135102 2022
38
Subcutaneous Panniculitis-like T-cell Lymphoma with a HAVCR2 Mutation Diagnosed After 10 Years of Treatment with Glucocorticoids and Cyclosporine as Lupus Panniculitis: A Case Report. 62
36171125 2022
39
Subcutaneous Panniculitis-like T-Cell Lymphoma with a Transformation to Lupus Erythematosus Panniculitis: A Case Report. 62
36466756 2022
40
Suggestions for a New Clinical Classification Approach to Panniculitis Based on a Mayo Clinic Experience of 207 Cases. 62
35849324 2022
41
Improvement of cutaneous inflammation and panniculitis in patients with dermatomyositis by the Janus kinase inhibitor baricitinib. 62
35318646 2022
42
Superficial (nodular) thrombophlebitis as a heterogeneous entity with distinctive clinico-pathological aspects: Correlation with the underlying conditions. 62
36178454 2022
43
Cytophagic Histiocytic Panniculitis and Kikuchi-Fujimoto-Like Lymphadenitis in a Patient With Systemic Lupus Erythematosus. 62
36237739 2022
44
Subcutaneous Panniculitis-Like T-Cell Lymphoma Revealed By Immunophenotyping of Necrosis. 62
35475979 2022
45
CT features associated with underlying malignancy in patients with diagnosed mesenteric panniculitis. 62
35843840 2022
46
Imaging follow-up in patients with mesenteric panniculitis. 62
35843838 2022
47
An Unusual Cause of Acute Abdominal Pain in Coronavirus Disease (COVID-19): Report of Two Cases. 62
36213717 2022
48
Polydioxanone thread insertion in combination with radio frequency treatment does not exhibit synergistic efficacy: Animal study with pigs. 62
34951734 2022
49
Mesenteric panniculitis various presentations and management: A single institute ten years, experience. 62
36045792 2022
50
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) with probable mesentery involvement with associated hemophagocytic syndrome (HPS) - how to treat it? 62
32924664 2022
Sources

Variations for Panniculitis

About this section
Sources

Expression for Panniculitis

About this section
Search GEO for disease gene expression data for Panniculitis.
Sources

Pathways for Panniculitis

About this section

Pathways related to Panniculitis according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.86 BTK CASP3 CSF3 FASLG HAVCR2 IFNG
2
MIF Mediated Glucocorticoid Regulation 64
Show member pathways
 13.56 BRAF BTK CASP3 CSF3 FAS FASLG
3
TGF-Beta Pathway 64
Show member pathways
 13.49 PSMB9 PSMB8 PSMB4 MYC IL2RA IFNG
4
Signal Transduction 66
13.41 BRAF BTK CASP3 FAS FASLG GZMB
5
RAF/MAP kinase cascade 66
Show member pathways
 13.32 PSMB9 PSMB8 PSMB4 NCAM1 MYC IL2RA
6
Cytokine Signaling in Immune system 66
Show member pathways
 13.14 PSMB9 PSMB8 PSMB4 NCAM1 MYC IL2RA
7
p75 NTR receptor-mediated signalling 66
Show member pathways
 12.82 OTULIN FASLG FAS CASP3 BTK
8
Toll-like receptor signaling pathway 74
Show member pathways
 12.75 MYC IL2RA FASLG FAS CASP3 BTK
9
Pre-NOTCH Expression and Processing 66
Show member pathways
 12.72 PSMB9 PSMB8 PSMB4 MYC GZMB
10
4-1BB Pathway 64
Show member pathways
 12.61 IFNG FASLG FAS CASP3 BRAF
11
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.58 PSMB8 MYC IL2RA IFNG CASP3
12
Programmed Cell Death 66
Show member pathways
 12.54 PSMB9 PSMB8 PSMB4 GZMB FASLG FAS
13
Chks in Checkpoint Regulation 64
Show member pathways
 12.44 CASP3 FAS FASLG MYC PSMB4 PSMB8
14
Mitotic G1 phase and G1/S transition 66
Show member pathways
 12.42 PSMB9 PSMB8 PSMB4 MYC
15
WNT Signaling 64
12.37 PSMB9 PSMB8 PSMB4 MYC
16
MAPK signaling pathway 74
12.33 BRAF CASP3 FAS FASLG MYC
17
Apoptosis and survival FAS signaling cascades 22
Show member pathways
 12.28 GZMB FASLG FAS CASP3 BTK
18
Antigen processing-Cross presentation 66
Show member pathways
 12.27 PSMB9 PSMB8 PSMB4 BTK
19
Apoptosis and Autophagy 3
Show member pathways
 12.26 TIA1 MYC GZMB FASLG FAS CASP3
20
MAPK Signaling: Mitogens 65
Show member pathways
 12.16 MYC IL2RA CASP3 BRAF
21
p53 Signaling 64
Show member pathways
 12.16 PSMB4 FASLG FAS CASP3
22
Colorectal Cancer Metastasis 64
12.14 MYC IFNG CASP3 BRAF
23
RIPK1-mediated regulated necrosis 66
Show member pathways
 12.13 GZMB FASLG FAS CASP3
24
Regulation by c-FLIP 66
Show member pathways
 12.1 FASLG FAS CASP3 BTK
25
Presenilin-Mediated Signaling 64
12.04 PSMB9 PSMB8 PSMB4 CASP3
26
IL2 signaling events mediated by STAT5 61
Show member pathways
 11.97 MYC IL2RA IFNG FASLG
27
Hematopoietic Stem Cells and Lineage-specific Markers 65
11.94 NCAM1 IL2RA IFNG CSF3
28
Spinal cord injury 74
11.92 MYC IFNG CASP3
29
IL12-mediated signaling events 61
Show member pathways
 11.91 IL2RA IFNG GZMB FASLG
30
NF-kappaB Signaling 3
11.84 PSMB8 OTULIN NCAM1 IL2RA IFNG HAVCR2
31
7q11.23 copy number variation syndrome 74
11.77 MYC FAS BTK
32
Innate Lymphoid Cells Differentiation 65
11.74 NCAM1 IL2RA IFNG GZMB
33
p73 transcription factor network 61
11.72 SERPINA1 MYC FAS
34
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 61
Show member pathways
 11.64 IL2RA IFNG FASLG CASP3
35
Hepatitis C and hepatocellular carcinoma 74
11.55 CASP3 FASLG MYC
36
IL-18 signaling pathway 74
11.51 FASLG FAS CASP3
37
Allograft rejection 74
11.4 IL2RA IFNG GZMB FASLG FAS CASP3
38
CTL Mediated Apoptosis 64
11.34 GZMB FASLG FAS CASP3
39
IL-15 Signaling and its Primary Biological Effects in Different Immune Cell Types 65
Show member pathways
 11.21 IL2RA IFNG GZMB FASLG FAS
40
Interactions of natural killer cells in pancreatic cancer 74
11.17 MYC IFNG GZMB
41
RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) 66
10.66 IFNG IL2RA
Sources

GO Terms for Panniculitis

About this section

Cellular components related to Panniculitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 proteasome complex GO:0000502 9.8 PSMB9 PSMB8 PSMB4
2 death-inducing signaling complex GO:0031264 9.56 FAS CASP3
3 spermatoproteasome complex GO:1990111 9.46 PSMB9 PSMB8
4 proteasome core complex GO:0005839 9.43 PSMB9 PSMB8 PSMB4
5 proteasome core complex, beta-subunit complex GO:0019774 9.1 PSMB9 PSMB8 PSMB4

Biological processes related to Panniculitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extrinsic apoptotic signaling pathway GO:0097191 9.85 IFNG FASLG FAS
2 apoptotic process GO:0006915 9.83 TIA1 IL2RA IFNG GZMB FASLG FAS
3 immune system process GO:0002376 9.8 PSMB9 PSMB8 OTULIN IL2RA HAVCR2 BTK
4 necroptotic signaling pathway GO:0097527 9.71 FASLG FAS
5 proteasomal protein catabolic process GO:0010498 9.63 PSMB4 PSMB8 PSMB9
6 activation-induced cell death of T cells GO:0006924 9.62 IL2RA FAS
7 proteolysis involved in protein catabolic process GO:0051603 9.02 PSMB9 PSMB8 PSMB4 GZMB

Molecular functions related to Panniculitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptidase activity GO:0008233 9.43 PSMB9 PSMB8 OTULIN GZMB CASP3
2 threonine-type endopeptidase activity GO:0004298 9.02 PSMB9 PSMB8 PSMB4
Sources

Sources for Panniculitis

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....